Fostemsavir: a new CD4 attachment inhibitor

Area of Science:

• Virology
• Infectious Diseases
• Pharmacology

Background:

• Antiretroviral (ARV) failure and drug resistance remain global challenges despite modern highly active antiretroviral therapy (HAART).
• The development of new ARV classes with novel mechanisms of action is crucial to overcome treatment resistance.
• No new classes of ARV drugs have been added to the treatment armamentarium for over a decade since the introduction of integrase inhibitors.

Purpose of the Study:

• To review the investigational HIV drug fostemsavir (FTR), an attachment inhibitor with a novel mechanism of action.
• To highlight FTR's potential to address challenges posed by ARV failure and drug resistance in HIV treatment.

Main Methods:

• Review of a Phase 3 clinical study evaluating fostemsavir (FTR) in HIV-infected, treatment-experienced individuals.
• Assessment of FTR's virologic activity, including plasma viral RNA reduction and achievement of viral suppression.

Main Results:

• Fostemsavir (FTR) demonstrated significant reduction in plasma viral RNA (1.21-1.73 log10 copies/ml) after 8 days of functional monotherapy.
• Up to 82% of patients achieved viral suppression (<50 copies/ml) at 48 weeks when treated with FTR and an optimized background ARV regimen.
• FTR exhibits activity regardless of viral tropism and lacks cross-resistance with existing ARV compounds.

Conclusions:

• Fostemsavir (FTR) is an investigational HIV drug with a novel mechanism of action.
• FTR shows virologic activity in HIV-infected treatment-experienced individuals, offering a new option for managing drug resistance.
• The attachment inhibitor mechanism of FTR provides a unique approach to overcoming ARV failure.